Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer have?
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer has 216 citations in the OpenAlex counts ScholarIQ stores.
When was Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer published?
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer has 2017 year in the ScholarIQ index.
What is the open-access status of Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer?
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer?
The DOI for Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer is on the source record.
What is the PMID of Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer?
The PMID for Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer is on the source record.
What is the OpenAlex record for Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer?
The OpenAlex for Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer is on the source record.